Financial analyst: Novo Nordisk's obesity treatment could triple market

Jefferies' analysts have consulted with an expert on obesity and diabetes treatments, and now, the investment banking company sees a real possibility that the market for obesity treatment will grow significantly.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk's novel weight loss drug Wegovy has the potential to at least double or triple the market, writes investment banking company Jefferies in a report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading